Gemtuzumab ozogamicin (solution)

Cat. No.: HY-109539A: FAQs
Data Sheet Handling Instructions

Molarity Calculator

Gemtuzumab ozogamicin (solution) is an antibody-drug conjugate (ADC) consisting of a humanized immunoglobulin (IgG4) antibody directed against CD33 that is conjugated to the cytotoxic agent Calicheamicin (HY-19609). Calicheamicin is a cytotoxic antibiotic. Gemtuzumab ozogamicin can be used for the research of acute myeloid leukemia (AML).

For research use only. We do not sell to patients.

Gemtuzumab ozogamicin (solution) Chemical Structure

CAS No. : 220578-59-6

Size		Stock
MOQ		Minimum order quantity
50 mg		Get quote
100 mg		Get quote
250 mg		Get quote
Other size		Get quote

Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other Forms of Gemtuzumab ozogamicin (solution):

Gemtuzumab ozogamicin Get quote

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

In Vitro

Gemtuzumab ozogamicin (1-250 ng/mL ; 72 hours) has cell cytotoxicity in CD33-positive cells^[1].
Gemtuzumab ozogamicin is an ADC. After binding of the antibody to CD33 and subsequent internalization, Gemtuzumab ozogamicin mediates cytotoxicity to CD33-positive myeloid cells primarily through induction of DNA damage and subsequent apoptosis^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:	CD33-positive and CD33-deficient cells (HL60, HL60R, Kasumi-1, MV4-11, MV4-11R, primary CD34-positive HSPCs and primary AML blasts)
Concentration:	0, 1, 5, 10, 25, 50, 100, 250 ng/mL
Incubation Time:	72 hours
Result:	Wildtype HL60 exhibited the highest sensitivity to GO (IC50=1.37 ng/mL), and almost all HL60 cells died at 5 ng/mL concentration.

Molecular Weight

151000 (average)

CAS No.

220578-59-6

SMILES

[Gemtuzumab ozogamicin (solution)]

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Yi Liu, et al. CD33-directed immunotherapy with third-generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and CD33-edited acute myeloid leukemia and hematopoietic stem and progenitor cells. Int J Cancer. 2022 Apr 1;150(7):1141-1155. [Content Brief]

[2]. Baron J, et al. Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia. Expert Rev Clin Pharmacol. 2018;11(6):549-559. [Content Brief]